Incozen Therapeutics
Oncology-focused biotechnology company based in Hyderabad, India, specializing in discovery and development of small-molecule cancer therapeutics. The organization operates via collaborative, risk-shared development models (partnering or incubation) to advance programs from target discovery and preclinical development toward clinical stages and regulatory approval.
Industries
Nr. of Employees
small (1-50)
Incozen Therapeutics
13th Floor, Manjeera Corporate, Trinity, K P H B Phase 3, Kukatpally, Hyderabad - 500072, Telangana, India
Patents
Methods of treating autoimmune, respiratory and inflammatory disorders by inhalation of roflumilast N-oxide
US-11103488-B2
View Details
Methods of treating autoimmune, respiratory and inflammatory disorders by inhalation of roflumilast N-oxide
US-11103488-B2
View DetailsProducts
Risk-Shared Drug Discovery & Development Collaborations
Collaborative partnerships where Incozen co-invests and shares risk with partners to discover and develop oncology small molecule drugs.
Incubation of Novel Oncology Programs
Development of partner-ready oncology drug programs on novel targets, incubated by Incozen for future collaboration and co-development.
Development of Small Molecule Oncology Therapeutics
Research and development of small molecule drugs targeting cancer pathways including DNA damage response, cyclin-dependent kinases, and immuno-oncology.
Development of Tenalisib (PI3K δ/γ Inhibitor)
Development of Tenalisib, a small molecule inhibitor targeting PI3K delta and gamma isoforms for treatment of lymphoma.
Risk-Shared Drug Discovery & Development Collaborations
Collaborative partnerships where Incozen co-invests and shares risk with partners to discover and develop oncology small molecule drugs.
Incubation of Novel Oncology Programs
Development of partner-ready oncology drug programs on novel targets, incubated by Incozen for future collaboration and co-development.
Development of Small Molecule Oncology Therapeutics
Research and development of small molecule drugs targeting cancer pathways including DNA damage response, cyclin-dependent kinases, and immuno-oncology.
Development of Tenalisib (PI3K δ/γ Inhibitor)
Development of Tenalisib, a small molecule inhibitor targeting PI3K delta and gamma isoforms for treatment of lymphoma.
Services
Partner associates to execute early-stage oncology small-molecule programs under a mutually agreed development plan with milestone-driven deliverables and flexible near-term/downstream milestone payments.
Incubation of partner-ready programs on novel oncology targets with co-investment and shared-risk agreements to advance programs toward clinical, regulatory, and licensing outcomes.
Partner associates to execute early-stage oncology small-molecule programs under a mutually agreed development plan with milestone-driven deliverables and flexible near-term/downstream milestone payments.
Incubation of partner-ready programs on novel oncology targets with co-investment and shared-risk agreements to advance programs toward clinical, regulatory, and licensing outcomes.
Expertise Areas
- Oncology drug discovery
- Small-molecule therapeutics
- Target identification and validation (DDR, CDK, PI3K)
- Translational research and preclinical development
Key Technologies
- Small-molecule medicinal chemistry
- Target identification and biological validation
- Isoform-selective kinase inhibitor development
- DNA damage response (DDR) targeting strategies